Loading... Please wait...
Sort by:


dossier-jpg.jpgDossier
reports present unbiased and concise analysis based on interviews with leading industry experts on important trends and challenging issues affecting the pharma industry today. 

  • Biomarkers and Companion Diagnostics - Payer views
    Learn More Biomarkers and Companion Diagnostics - Payer views
    Winning Payer Support for Companion Diagnostics & Biomakers How can you positively influence payer attitudes to biomarkers and companion diagnostics (CDx)? Biomarkers and CDx are critical to realising the...
  • Evidence Matters – Why Pharma Needs to Get Serious about Data
    Learn More Evidence Matters – Why Pharma Needs to Get Serious about Data
    Real World Evidence: Creating a forward-focused strategy In today’s highly scrutinised drugs marketplace, pockets continue to be squeezed and the list of demands from every quarter lengthens. Against this...
  • Charting MSL Activity and Performance (2017)
    Learn More Charting MSL Activity and Performance (2017)
    A unique survey-based report providing key insights and actionable intelligence about MSL activity and performance. Charting MSL Activity and Performance (2017) distils key findings from one of the most comprehensive...
  • Real World Data: Meeting Payer Needs
    Learn More Real World Data: Meeting Payer Needs
    How to adjust your Real World Data provision to address the real needs of payers Drug costs are spiralling upwards and so too are frustration levels. Payers with stretched budgets are still struggling to make the case...
  • How Payers Want to Work With Pharma
    Learn More How Payers Want to Work With Pharma
    How to effectively engage US and EU payers You’re speaking to payers, but are they listening?  Do you really understand their needs and concerns?  Is your approach to payer negotiations getting your...
  • Medical Affairs in Orphan Drugs
    Learn More Medical Affairs in Orphan Drugs
    Orphan drugs: Is your medical affairs team leading the fray or lagging behind?  Traditional commercial models simply don’t work for orphan drugs, not least because the physician and patient populations are so...
  • Pulling the Data Puzzle Together: Being Payer-Centric
    Learn More Pulling the Data Puzzle Together: Being Payer-Centric
    Mapping data with payer needs. How to solve the data puzzle.  Everyone is talking about data. What’s being collected; how robust is it; what does it prove; who should be told? From the all-important payer...
  • Charting the Orphan Drug Development Pipeline
    Learn More Charting the Orphan Drug Development Pipeline
    Which are the most exciting areas of orphan drug research and where are the best opportunities? Global sales of drugs for orphan indications were estimated to be $114 billion in 2016, with sales forecast to rise to $209...
  • Biosimilars in Emerging Markets (2017)
    Learn More Biosimilars in Emerging Markets (2017)
    Biosimilars: Make the most of high risk emerging market opportunities  Emerging biosimilars markets are currently a $5billion opportunity with even more growth potential ahead. Lower drug costs and improved patient...
  • Biosimilars: US Payer Perspectives (2017)
    Learn More Biosimilars: US Payer Perspectives (2017)
    Will biosimilar provide a ‘magic bullet’ to drug prices in the US? Payers speak out…  Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers...
  • The Future of Biobetters
    Learn More The Future of Biobetters
    Strategies for success in the biobetter market How can you successfully position biobetter products in the increasingly crowded branded biologic/biosimilar space? With the prospect of improving patient adherence,...
  • Real World Data Capabilities: Benchmarking Pharma Companies
    Learn More Real World Data Capabilities: Benchmarking Pharma Companies
    Is Real World Data giving your market access the power charge it needs? Real World Data (RWD) and Real World Evidence (RWE) are gaining traction across the industry. The front runners are already exploring new ways to...
  • Overcoming Market Access Barriers to High Value Drugs
    Learn More Overcoming Market Access Barriers to High Value Drugs
    Overcoming market access barriers to high-value drugs How can you breakthrough the market access barriers that face high-value oncology and immunotherapy products in the EU5 and US? Pharma faces unprecedented demands...
  • Biosimilars: European Payer Perspectives (2017)
    Learn More Biosimilars: European Payer Perspectives (2017)
    What is the future for biosimilars in the EU? What issues do EU Payers think will impact adoption, pricing and reimbursement of biosimilars? In January 2016 Samsung Bioepis launched Benepali, a biosimilar version of...
  • The Future of Medical Affairs
    Learn More The Future of Medical Affairs
    What are the future opportunities and challenges for medical affairs? As the interface between companies and KOLs, HCPs, payers and patients, medical affairs has grown rapidly in importance.  And demands are set to...
  • Defending Against Biosimilars: Originator strategies
    Learn More Defending Against Biosimilars: Originator strategies
    Battle of the biologics: How to survive The onward march of biologics has shaped a brave new world for drug manufacturers with conflicting rules and regulations and an eclectic mix of individual players to contend with...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved